Most women diagnosed with high-grade serous ovarian cancer (HGSC) develop recurrent disease and chemotherapy resistance, despite initially responding to treatment. The genomic characteristics of HGSC samples collected at initial surgery have been extensively studied. However, due to challenges of sample collection following treatment, much less is known about the molecular features of recurrent disease. Our recent studies have identified mechanisms of acquired resistance and biomarkers in recurrent HGSCs that could lead to improved treatment approaches.
Introduction
High-grade serous ovarian cancer (HGSC) accounts for 75% of epithelial ovarian cancers. The 5-year survival rate for women diagnosed with HGSC is between 35% and 40%, due to primary treatment resistance in 15%-25% of patients and emergence of chemotherapy resistance in a majority of the remaining women [1] [2] [3] . The genomic landscape of primary HGSC has been extensively analysed, identifying that HSGCs are characterised by high levels of copy number change but few recurrent simple somatic mutations [4] . A number of studies have previously identified primary and acquired chemotherapy resistance mechanisms [5] [6] [7] [8] . However, these studies have consistently only examined small numbers of recurrent samples as surgery is rarely carried out in the recurrent setting.
Our recent study utilised whole genome sequencing of 114 tumour samples from 92 patients to further increase our understanding of mechanisms of primary and acquired chemotherapy resistance [9] . Here, we summarise some of the findings from this study and more recent work.
A disease driven by chromosomal rearrangement
Consistent with our previous finding that TP53 mutation occurs in almost all HGSC [10] , we identified TP53 mutations in all but one of the primary HGSC samples. In addition, numerous structural variants (SVs) were identified. Importantly, inactivation of the tumour suppressors RB1 and NF1 by gene breakage was much more common than point mutational inactivation previously observed in exome sequencing studies. Chromothripsis and breakage-fusion-bridge cycles were infrequent, however, highly complex focal structural rearrangement events were observed. No recurrent gene fusion driver events were identified in primary tumour samples.
Primary treatment response
As we have previously found, amplification of CCNE1 was associated with resistance to primary treatment [5, 9] , and patients with homologous recombination repair defects, including germline BRCA1/2 mutations, were enriched in the primary sensitive cohort [9, 11] . The mutational burden was substantially reduced in primary resistant versus sensitive patients, perhaps reflecting rapid expansion of an aggressive, clonally dominant disease in patients with a short progression-free survival.
Acquired chemotherapy resistance
Four mechanisms of acquired resistance were found in the analysis of recurrent samples, and these were present in approximately half of the cases in the cohort. Of the acquired resistant cases with germline BRCA1/2 mutations, secondary mutations in BRCA1/2 that restored the open reading frame, leading to functional homologous recombination repair, were observed in half. Previous studies have shown that BRCA1/2 reversion mutations lead to chemoresistance to platinum-based chemotherapy and PARP inhibitors [8, 12] . Notably, two patients were found to have more than one reversion mutation, including a rapid autopsy patient in which 11 BRCA2 reversions were observed across the 17 sites sampled at autopsy [9] , highlighting the plasticity of the HGSC genome.
In a second autopsy case with a germline BRCA1 mutation no reversion mutations were evident, however the tumour samples were characterised by extensive desmoplastic stroma, which was not present in the primary sensitive tumour sample [9] . In pancreatic cancer, desmoplasia is associated with reduced chemotherapy uptake and subsequently increased resistance [13] .
One patient had somatic methylation of the BRCA1 promoter in the primary sensitive tumour sample but not in the recurrent resistant sample, which had BRCA1 expression comparable to BRCA1 wild-type samples [9] . It is hypothesised that restored BRCA1 expression in the recurrent sample would result in proficient homologous recombination repair and subsequently chemoresistance.
The final mechanism identified involved SVs in the multidrug resistance gene ABCB1, resulting in fusion of the promoter and non-coding exon 1 of an upstream gene SLC25A40 to the coding exons of ABCB1 and subsequent high levels of ABCB1 expression. This fusion was observed in four patients of the acquired resistance cohort, and in a further four recurrent ascites that were part of a validation cohort, a total of 8% of all recurrent samples tested. ABCB1 encodes P-glycoprotein, which is an efflux pump for a number of chemotherapies commonly used in the treatment of HGSC. All patients with an SLC25A40-ABCB1 fusion had been treated with at least one P-glycoprotein substrate before collection of the tumour sample with the fusion, and had shown resistance to that chemotherapy.
The BRCA1/2 reversion mutations and the ABCB1 SVs were mostly found to be subclonal, suggesting that multiple resistance mechanisms exist within each patient or that the subclonal resistant cells interact and protect sensitive cells.
Development of biomarkers
For the knowledge of resistance mechanisms to be of value in the clinical setting, a non-invasive method to identify patients that harbour each mechanism is needed in order to direct treatment to more effective therapies. Circulating tumour DNA (ctDNA) is an ideal non-invasive biomarker that does not rely on the development of ascites, and serial sampling can easily be achieved to examine dynamics of resistance mechanisms over time.
Recently, we found that BRCA1/2 reversion mutations can be identified in the circulating cell free DNA from plasma samples from patients with germline BRCA1/2 mutations [14] . Reversions were never detected in patients where a reversion was not seen in the matched tumour sample, and in an autopsy case with multiple reversions detected in tumour samples, multiple reversions were also detected in ctDNA. The reversions detected in the ctDNA were those that were present at higher frequency in the tumour samples. The utility of an assay to identify reversions in ctDNA is the subject of ongoing studies directed to improving sensitivity of detection and understanding the timing of reversion relative to clinical progression.
Discussion Conclusion
The mechanisms of acquired chemoresistance are heterogeneous, both within and between patients. Therefore, we will require diverse approaches and specific biomarkers in order to resensitise patients to standard chemotherapies. Further work remains to elucidate the mechanisms of acquired chemoresistance in all patients, and to determine how resistance is conferred in patients whose resistance mechanisms are subclonal. 
